Financing ·
Amends convertible notes to accelerate maturity date to December 1, 2026 and removes affirmative covenants
EVFMEvofem Biosciences, Inc.
Evofem Biosciences entered into a fifth amendment to its Securities Purchase Agreement with Adjuvant Global Health Technology Fund. The amendment accelerates the maturity of the outstanding convertible promissory notes to the earlier of December 1, 2026, or a Change of Control event. Additionally, the company removed certain affirmative covenants from the agreement and restricted prepayment prior to the new maturity date without investor consent. Evofem Biosciences operates in the biotechnology sector, developing therapies for women's health.